The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer

Overview

Journal AJR Am J Roentgenol

Specialties Oncology
Radiology

Date 2016 Oct 12

PMID 27726427

Citations 38

Authors

Sara Sheikhbahaei

Esther Mena

Anusha Yanamadala

Siddaling Reddy

Lilja B Solnes

Jason Wachsmann

Rathan M Subramaniam

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this article is to summarize the evidence regarding the role of FDG PET/CT in treatment response assessment and surveillance of lung cancer and to provide suggested best practices.

Conclusion: FDG PET/CT is a valuable imaging tool for assessing treatment response for patients with lung cancer, though evidence for its comparative effectiveness with chest CT is still evolving. FDG PET/CT is most useful when there is clinical suspicion or other evidence for disease recurrence or metastases. The sequencing, cost analysis, and comparative effectiveness of FDG PET/CT and conventional imaging modalities in the follow-up setting need to be investigated.

Citing Articles

Comparison of Al[F]-NOTA-FAPI-04 PET/CT and [F]-FDG PET/CT in a patient with lung cancer and pulmonary tuberculosis: a case report and literature review.

Qin J, Yu J, Wei Y Front Oncol. 2025; 15:1470132.

PMID: 39963103 PMC: 11830580. DOI: 10.3389/fonc.2025.1470132.

Value of [F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy.

Zhang Y, Xu M, Wang Y, Yu F, Chen X, Wang G Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39820598 DOI: 10.1007/s00259-025-07084-7.

Uncertainty-aware automatic TNM staging classification for [F] Fluorodeoxyglucose PET-CT reports for lung cancer utilising transformer-based language models and multi-task learning.

Barlow S, Chicklore S, He Y, Ourselin S, Wagner T, Barnes A BMC Med Inform Decis Mak. 2024; 24(1):396.

PMID: 39695672 PMC: 11657742. DOI: 10.1186/s12911-024-02814-7.

Molecular Imaging Biomarkers for Early Cancer Detection: A Systematic Review of Emerging Technologies and Clinical Applications.

Malik M, Alqahtani M, Hadadi I, Kanbayti I, Alawaji Z, Aloufi B Diagnostics (Basel). 2024; 14(21).

PMID: 39518426 PMC: 11545511. DOI: 10.3390/diagnostics14212459.

Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis.

Kairemo K, Macapinlac H, Gouda M, Subbiah V Diagnostics (Basel). 2024; 14(17).

PMID: 39272672 PMC: 11393986. DOI: 10.3390/diagnostics14171886.